Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease

Immunologic Research

Volumn 31, Issue 3, 2005, Pages 165-176

  Iribarren, Pablo ^a   Zhou, Ye ^a   Hu, Jinyue ^a   Le, Yingying ^a,b   Wang, Ji Ming ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Alzheimer disease; Amyloid ; Formyl peptide receptor; Inflammation

Indexed keywords

AMYLOID BETA PROTEIN; CELL SURFACE PROTEIN; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR LIKE 1; FORMYLPEPTIDE RECEPTOR LIKE 2; G PROTEIN COUPLED RECEPTOR; NEUROTOXIN; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHEMOTAXIS; CYTOTOXICITY; GLIA CELL; HUMAN; INFLAMMATORY DISEASE; INTERNALIZATION; MEDIATOR RELEASE; MICROGLIA; MONONUCLEAR PHAGOCYTE; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CYTOKINES; HUMANS; MICROGLIA; PHAGOCYTES; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; SIGNAL TRANSDUCTION;

EID: 18244407519     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:31:3:165     Document Type: Review

References (96)

1. Chao CC, Hu S, Peterson PK: Glia: the not so innocent bystanders. J Neurovirol 1996;2:234-239.
2. Del Rio Hortega P: Microglia; in Penfield W (ed): Cytology and Cellular Pathology of the Nervous System. New York, Paul Hoeber, 1932, pp 481-534.
3. Lawson LJ, Perry VH, Dri P, Gordon S: Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990;39:151-170.
4. Perry VH: Microglia resident macrophages of the CNS; in Perry VH (ed): Macrophages and the Nervous System. Austin, TX, RG Landes, 1994, pp 6-27.
5. Fedoroff S, Zhai R, Novak JP: Microglia and astroglia have a common progenitor cell. J Neurosci Res 1997;50:477-486.
6. Flaris NA, Densmore TL, Molleston MC, Hickey WF: Characterization of microglia and macrophages in the central nervous system of rats: definition of the differential expression of molecules using standard and novel monoclonal antibodies in normal CNS and in four models of parenchymal reaction. Glia 1993;7:34-40.
7. Reid DM, Perry VH, Andersson PB, Gordon S: Mitosis and apoptosis of microglia in vivo induced by an anti-CR3 antibody which crosses the blood-brain barrier. Neuroscience 1993;56:529-533.
8. Becher B, Antel JP: Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia. Glia 1996;18:1-10.
9. Cui YH, Le Y, Gong W, et al: Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells. J Immunol 2002;168:434-442.
10. Giulian D, Chen J, Ingeman JE, George JK, Noponen M: The role of mononuclear phagocytes in wound healing after traumatic injury to adult mammalian brain. J Neurosci 1989;9:4416-4429.
11. Amat JA, Ishiguro H, Nakamura K, Norton WT: Phenotypic diversity and kinetics of proliferating microglia and astrocytes following cortical stab wounds. Glia 1996;16:368-382.
12. Giulian D, Woodward J, Young DG, Krebs JF, Lachman LB: Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 1988;8:2485-2490.
13. Graeber MB, Streit WJ, Kreutzberg GW: Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells. J Neurosci Res 1988;21:18-24.
14. Chao CC, Hu S, Sheng WS, Bu D, Bukrinsky MI, Peterson PK: Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 1996;16:276-284.
15. Kaltschmidt C, Kaltschmidt B, Lannes-Vieira J, et al: Transcription factor NF-kappa B is activated in microglia during experimental autoimmune encephalomyelitis. J Neuroimmunol 1994;55:99-106.
16. Sadik K, Wilcock G: The increasing burden of Alzheimer disease. Alzheimer Dis Assoc Disord 2003; 3:S75-S79.
17. Dickson DW: The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56:321-339.
18. Scheff SW, Price DA: Synaptic density in the inner molecular layer of the hippocampal dentate gyrus in Alzheimer disease. J Neuropathol Exp Neurol 1998;57:1146-1153.
19. Selkoe D: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
20. Wegiel J, Wisniewski HM, Dziewiatkowski J, et al: The origin of amyloid in cerebral vessels of aged dogs. Brain Res 1995;705:225-234.
21. Wisniewski KE, Wisniewski HM, Wen GY: Occurrance of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985;17: 278-282.
22. Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ: Evidence that the 42- and 40-amino acid forms of amyloid β protein are generated from the β-amyloid precursor protein by different protease activities. Proc Natl Acad Sci USA 1996;93:13,170-13,175.
23. Selkoe DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999;399 (Suppl 6738):A23-A31.
24. Eikelenboom P, Rozemuller JM, van Muiswinkel FL: Inflammation and Alzheimer's disease: relationships between pathogenic mechanisms and clinical expression. Exp Neurol 1998;154:89-98.
25. Cotter RL, Burke WJ, Thomas VS, Potter JF, Zheng J, Gendelman HE: Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity. J Leukoc Biol 1999;65:416-427.
26. McGeer PL, McGeer EG: Inflammation of the brain in Alzheimer's disease: implications for therapy. J Leukoc Biol 1999;65:409-415.
27. McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291.
28. Uchihara T, Akiyama H, Kondo H, Ikeda K: Activated microglial cells are colocalized with perivascular deposits of amyloid-β protein in Alzheimer's disease brain. Stroke 1997;28:1948-1950.
29. Rogers J, Lue LF: Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem Int 2001; 39:333-340.
30. Lue LF, Rydel R, Brigham EF, et al: Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 2001;35:72-79.
31. Walker DG, Kim SU, McGeer PL: Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J Neurosci Res 1995;40:478-493.
32. Shen Y, Li R, McGeer EG, McGeer PL: Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res 1997;769:391-395.
33. Strohmeyer R, Shen Y, Rogers J. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res Mol Brain Res 2000;81:7-18.
34. Walker DG, Lue LF, Beach TG: Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging 2001;22: 957-966.
35. Fiala M, Zhang L, Can X, et al: Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol Med 1998;4: 480-489.
36. Haga S, Ikeda K, Sato M, Ishii T: Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res 1993;601:88-94.
37. Haga S, Aizawa T, Ishii T, Ikeda K: Complement gene expression in mouse microglia and astrocytes in culture: comparisons with mouse peritoneal macrophages. Neuosci Lett 1996;216:191-194.
38. Weldon DT, Rogers SD, Ghilardi JR, et al: Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 1998;18:2161-2173.
39. Terry RD, Wisniewski HM: Pathology and pathogenesis of dementia; in Fields WS, (ed): Neurological and Sensory Disorders in the Elderly. New York, Stratton, 1975, pp 135-150.
40. Davis JB, McMurray HF, Schubert D: The amyloid beta-protein of Alzheimer's disease is chemotactic for mononuclear phagocytes. Biochem Biophys Res Commun 1992;189:1096-1100.
41. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike, JD: Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 1996;382:716-719.
42. Van SD, Chen X, Fu J, et al: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-691.
43. Nakai M, Hojo K, Taniguchi T, et al: PKC and tyrosine kinase involvement in amyloid beta (25-35)-induced chemotaxis of microglia. Neuroreport 1998;9:3467-3470.
44. McDonald DR, Brunden KR, Landreth GE: Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci 1997; 17:2284-2294.
45. Lorton D: Beta-amyloid-induced IL-1 beta release from an activated human monocyte cell line is calcium- and G-protein-dependent. Mech Ageing Dev 1997;94:99-211.
46. Lorton D, Schaller J, Lala A, De Nardin E: Chemotactic-like receptors and Abeta peptide induced responses in Alzheimer's disease. Neurobiol Aging 2000;21: 463-473.
47. Le Y, Gong W, Tiffany HL, et al: Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci 2001;21:RC123.
48. Le Y, Murphy PM, Wang JM: Formyl-peptide receptors revisited. Trends Immunol 2002;23:541-548.
49. Tiffany HL, Lavigne MC, Cui YH, et al: Amyloid-beta induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain. J Biol Chem 2001;276:23,645-23,652.
50. Yazawa H, Yu ZX, Takeda K, et al: Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J 2001;15:2454-2462.
51. LeY, Gong W, Li B, et al: Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J Immunol 1999;163:6777-6784.
52. Mills J, Reiner PB: Regulation of amyloid precursor protein cleavage. J Neurochem 1999;72:443-460.
53. Shaffer LM, Dority MD, Gupta-Bansal R, Frederickson RC, Younkin, S. G., Brunden KR: Amyloid beta protein (A beta) removal by neuroglial cells in culture. Neurobiol Aging 1995;16:737-745.
54. Chung H, Brazil MI, Soe TT, Maxfield FR: Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J Biol Chem 1999:274:32,301-32,308.
55. Weltzien RB, Pachter JS. Visualization of beta-amyloid peptide (Abeta) phagocytosis by human mononuclear phagocytes: dependency on Abeta aggregate size. J Neurosci Res 2000;59:522-527.
56. DeWitt DA, Perry G, Cohen M, Doller C, Silver J: Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp Neurol 1998;149: 329-340.
57. Schenk D, Barbour R, Dunn W, et al: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400: 173-177.
58. Hashimoto Y, Niikura T, Tajima H, et al: A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. Proc Natl Acad Sci USA 2001;98:6336-6341.
59. Tajima H, Niikura T, Hashimoto Y, et al: Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer's disease-related insults. Neurosci Lett 2002;324:227-231.
60. Ying G, Iribarren P, Zhou Y, et al: Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. J Immunol 2004;172:7078-7085.
61. Nolte C, Moller T, Walter T, Kettenmann H: Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton. Neuroscience 1996;73:1091-1107.
62. Tanabe S, Heesen M, Yoshizawa I, et al: Functional expression of CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes. J Immunol 1997; 159:905-911.
63. Boddeke EWGM, Meigel I, Frentzel S, et al: Cultured rat microglia express functional-chemokine receptors. J Neuroimmunol 1999;98:176-184.
64. Yao J, Harvath L, Gilbert DL, Colton CA: Chemotaxis by a CNS macrophage, the microglia. J Neurosci Res 1990;27:36-42.
65. Lacy M, Jones J, Whittemore SR, Haviland DL, Wetsel RA, Barnum SR: Expression of the receptor for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. J Neuroimmunol 1995;61:71-78.
66. Muller-Ladner U, Jones JL, Wetsel RA, Gay S, Raine CS, Barnum SR: Enhanced expression of chemotactic receptors in multiple sclerosis lesions. J Neurol Sci 1996;144:135-141.
67. Ulevitch RJ, Tobias PS: Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol 1999;11:19-22.
68. Brazil TJ, Rossi AG, Haslett C, McGorum B, Dixon PM, Chilvers ER: Priming induces functional coupling of N-formylmethionyl-leucyl-phenylalanine receptors in equine neutrophils. J Leukoc Biol 1998;63:380-388.
69. Norgauer J, Eberle M, Fay SP, Lemke HD, Sklar LA: Kinetics of N-formyl peptide receptor up-regulation during stimulation in human neutrophils. J Immunol 1991;146:975-980.
70. Karlsson A, Markfjall M, Stromberg N, Dahlgren C: Escherichia coli-induced activation of neutrophil NADH-oxidase: lipopolysaccharide and formylated peptides act synergistically to induce release of reactive oxygen metabolites. Infect Immun 1995;63:4606-4612.
71. Goldman DW, Enkel H, Gifford LA, Chenoweth DE, Rosenbaum JT. Lipopolysaccharide modulates receptors for leukotriene B4, C5a, and formyl-methionyl-leucylphenylalanine on rabbit polymorphonnuclear leukocytes. J Immunol 1986;137:1971-1976.
72. Sica A, Saccani A, Borsatti A, et al: Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes. J Exp Med 1997; 185:969-974.
73. Katona IM, Ohura K, Allen JB, Walh LM, Chenoweth DE, Wahl SM: Modulation of monocyte chemotactic function in inflammatory lesions: role of inflammatory mediators. J Immunol 1997;146:708-714.
74. Sozzani S, Ghezzi S, Iannolo G, et al: Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J Exp Med 1998;187:439-444.
75. Cui YH, Le Y, Zhang X, et al: Up-regulation of formyl peptide receptor 2 (FPR2) in murine microglial cells by TNFα. Neurobiol Dis 2002;10:366-377.
76. Lacroix S, Feinstein D, Rivest S: The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations. Brain Pathol 1998;8:625-640.
77. Rollins BJ: Chemokines. Blood 1997;90:909-928.
78. Le Y, Gong W, Shen W, Li B, Dunlop NM, Wang JM: A burgeoning family of biological mediators: chemokines and chemokine receptors. Arch Immunol Ther Exp (Warsz) 2000;48:143-150.
79. Hull M, Lieb K, Fiebich BL: Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs. Curr Med Chem 2002;9:83-88.
80. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
81. Gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
82. Mosser DM: The many faces of macrophage activation. J Leukoc Biol 2003;73:209-212.
83. Tamura S, Hanada M, Ohnishi M, Katsura K, Sasaki M, Kobayashi T: Regulation of stress-activated protein kinase signaling pathways by protein phosphatases. Eur J Biochem 2002;269:1060-1066.
84. Shanley TP, Vasi N, Denenberg A, Wong HR: The serine/threonine phosphatase, PP2A: endogenous regulator of inflammatory cell signaling. J Immunol 2001; 166:966-972.
85. Pahan K, Sheikh FG, Namboodiri AM, Singh I: Inhibitors of protein phosphatase 1 and 2A differentially regulate the expression of inducible nitric-oxide synthase in rat astrocytes and macrophages. J Biol Chem 1998;273:12,219-12,226.
86. Iribarren P, Cui YH, Le Y, et al: IL-4 down-regulates lipopolysaccharide-induced formyl peptide receptor 2 in murine microglial cells by inhibiting the activation of mitogen-activated protein icinases. J Immunol 2003;171: 5482-5488.
87. Abbas N, Bednar I, Mix E, et al: Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J Neuroimmunol 2002; 126:50-57.
88. Letterio JJ, Roberts AB: Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16: 137-161.
89. Shull MM, Ormsby I, Kier AB, et al: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359:693-699.
90. Kulkarni AB, Huh CG, Becker D, et al: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770-774.
91. Ulich TR, Yin S, Guo K, Yi ES, Remick D, del Castillo J: Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am J Pathol 1991;138:1097-1101.
92. Perrella MA, Hsieh CM, Lee WS, et al: Arrest of endotoxin-induced hypotension by transforming growth factor beta1. Proc Natl Acad Sci USA 1996;93:2054-2059.
93. Imai K, Takeshita A, Hanazawa S: Transforming growth factor-beta inhibits lipopolysaccharide-stimulated expression of inflammatory cytokines in mouse macrophages through downregulation of activation protein 1 and CD14 receptor expression. Infect Immun 2000;68:2418-2423.
94. Wyss-Coray T, Lin C, Yan F, et al: TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 2001;7:612-618.
95. Frautschy SA, Yang F, Calderon L, Cole GM: Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits. Neurobiol Aging 1996;17:311-321.
96. Le Y, Iribarren P, Gong W, Cui Y, Zhang X, Wang JM: TGF-betal disrupts endotoxin signaling in microglial cells through Smad3 and MAPK pathways. J Immunol 2004;173:962-968.